Preliminary clinical performance data for professional use COVID-19 rapid diagnostic test

By |2021-05-20T11:50:00+01:00May 1st, 2020|

Mologic is pleased to announce that following rigorous independent assessment by St George’s, University London and Liverpool School of Tropical Medicine, our point-of-need, professional use, rapid diagnostic test (RDT) for COVID-19 has achieved preliminary clinical performance data of 98% sensitivity at days 14-21 and specificity of 96%. The test [...]

Mologic launches new lab-based COVID-19 antibody tests

By |2021-05-14T14:21:05+01:00April 20th, 2020|

  Follows successful validation by Liverpool School of Tropical Medicine and St George’s, University of London With manufacturing support from Omega Diagnostics, the laboratory-based test aims to deliver up to 46,000 results per day Health services and key worker communities in the UK and Africa will be prioritised for [...]

COVID-19 Update – 17 April 2020

By |2021-05-20T11:47:58+01:00April 17th, 2020|

We are pleased to announce that Mologic’s COVID-19 laboratory and point of need antibody tests have both graduated from research and development, achieved design freeze and are ready for manufacture. Both COVID-19 tests have been independently assessed by the Liverpool School of Tropical Medicine (LSTM) and St George’s [...]

Mologic awarded c.£1 million by UK government to develop rapid diagnostic test for COVID-19

By |2021-05-20T11:44:31+01:00March 6th, 2020|

Grant awarded as part of UK government’s £46 million international COVID-19 prevention and research package Test will support global efforts to prevent further spread of COVID-19 by enabling rapid diagnosis at the point-of-need Funding will also initiate Mologic’s research for novel vaccine candidates Bedfordshire, UK, 6th March 2020: Mologic [...]

Mologic and Institut Pasteur de Dakar launch accelerated programme to develop rapid diagnostic test for Ebola

By |2021-05-14T14:08:37+01:00February 25th, 2020|

Project aims to facilitate early diagnosis and support efforts to stop the Ebola Virus Disease epidemic Rapid point-of-need test critical to boosting surveillance and response to global viral outbreaks Partnership builds on BIOASTER’s early R&D during the 2014-2016 Ebola outbreak   Bedfordshire, UK, 25 February 2020: Mologic Ltd, a [...]

BIOASTER Awarded Grant for the Development of Rapid Diagnostics for Neglected Tropical Diseases

By |2021-05-20T11:43:40+01:00January 9th, 2020|

BIOASTER receives $885K grant from the Bill & Melinda Gates Foundation to develop Onchocerciasis advanced rapid diagnostic with Mologic Ltd Lyon, January 07th, 2020 BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, today announced it has received a grant in the field of diagnosis of Neglected [...]

Mologic launches clinical trial for validation of point-of-care COPD exacerbation alert system

By |2021-05-14T14:32:01+01:00November 20th, 2019|

Mologic launches clinical trial for validation of point-of-care COPD exacerbation alert system COPE-WEL study aims to validate Headstart® test for early detection and monitoring of pulmonary exacerbation of COPD Headstart is a non-invasive self-test that detects lung biomarkers in the urine Observational, multi-centre validation trial carried out in collaboration [...]

Mologic pushing the boundaries of high sensitivity lateral flow technology – Charlton Morris Life Science

By |2021-05-20T11:40:41+01:00October 7th, 2019|

Being recognised as a company pushing the boundaries of high sensitivity lateral flow technology, Charlton Morris Life Science recently visited Mologic to speak with our Co-Founder and Chief Scientific Officer, Professor Paul Davis, the originator of the Clearblue pregnancy test, the world’s first commercial application of lateral flow technology. [...]

Go to Top